Results 181 to 190 of about 3,144,476 (264)

Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer

Translational Oncology, 2023
Mehrdad Hashemi, Nastaran Esbati, Mohsen Rashidi, Sadaf Gholami, Rasoul Raesi, Seyed Shahabadin Bidoki, Mohammad Ali Sheikh Beig Goharrizi, Yasamin Sadat Mousavi Motlagh, Ramin Khorrami, A. Tavakolpournegari, N. Nabavi, Rongjun Zou, Leila Mohammadnahal, M. Entezari, A. Taheriazam, K. Hushmandi   +15 more
semanticscholar   +1 more source

A Clinical Guidance for the Management of Patients With Hepatoid Adenocarcinoma and A Case Series

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Hepatoid adenocarcinoma (HAC) is a rare extrahepatic tumor of non‐germ cell origin that morphologically resembles hepatocellular carcinoma (HCC). HAC has a propensity to metastasize to the liver and therefore may be mistaken for HCC. There is a lack of standardized treatment protocols, and further studies are needed to evaluate the benefit of ...
Christina Liava, Sudhakar Venkatesh, Michael S. Torbenson, Patrick S. Kamath, Moira Hilscher   +4 more
wiley   +1 more source

Establishment and Characterization of MCA23, a Novel Mouse Intrahepatic Cholangiocarcinoma Cell Line

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Intrahepatic cholangiocarcinoma (ICC) is an aggressive type of malignancy. Recent advancements have highlighted the importance of the tumor immune microenvironment in therapeutic responses and prognosis. However, the lack of a mouse‐derived ICC cell line and current mouse models limit explorations of the TME in ICC.
Yuchao He, Yi Luo, Liwei Chen, Yu Wang, Bei Liu, Mengting Sun, Wenchen Gong, Xiangdong Tian, Lin Guo, Qin Zhang, Qiang Wu, Lu Chen, Hua Guo   +12 more
wiley   +1 more source

Crosstalk Between Intratumoral Microbes and Tumor Immunity: Implications for Tumor Therapy

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Emerging studies indicate that microbes are present in tumor cells and immune cells. Intratumoral microbiota (ITM) constitute an important component of the tumor immune microenvironment (TIME) and have an important impact on tumor progression and treatment. Objective Through the general elaboration of ITM represented by bacteria and
Fengxue Li, Lili Qiao, Xinquan Liang, Yingying Zhang, Ning Liang, Jian Xie, Guodong Deng, Yuying Hao, Pingping Hu, Xue Wu, Fangjie Ding, Can Feng, Yiming Mu, Jiandong Zhang   +13 more
wiley   +1 more source

Minimal residual disease in solid tumors: Clinical applications and future directions

Cancer, Volume 132, Issue 3, 1 February 2026.
Abstract Minimal residual disease (MRD) refers to the presence of residual cancer cells or tumor‐derived fragments that persist after treatment and remain undetectable by conventional imaging or protein‐based assays. Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker for MRD detection.
Theresa Abdo, Ahmad Alhalabi, Sacha Yaghi, Mohammad Aloran, You Li, María Herrán, Rami Tfayli, Thomas A. Samuel, Zeina Nahleh   +8 more
wiley   +1 more source

Longitudinal Analysis of Manually and Automatically Classified Circulating Tumor Biomarkers and their Prediction of Survival in Metastatic Colorectal Cancer

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 403-413, February 2026.
Circulating tumor cells (CTCs) and tumor‐derived extracellular vesicles (tdEVs) are promising biomarkers for predicting survival and informing treatment decisions in metastatic colorectal cancer (mCRC); yet their clinical application remains limited. In this study, we analyzed CellSearch image archives from 446 patients with mCRC treated in the CAIRO2 ...
Maddalena Centanni, Afroditi Nanou, Leon W. M. M. Terstappen, Kees J. A. Punt, Frank A.W. Coumans, Mats O. Karlsson, Lena E. Friberg   +6 more
wiley   +1 more source

Surufatinib plus anti‐PD‐1/PD‐L1 antibody as second‐line therapy for advanced biliary tract cancer: A single‐centre investigator‐initiated trial

Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
Abstract Objective To explore the efficacy and safety of surufatinib in combination with anti‐PD‐1/PD‐L1 antibodies (with or without chemotherapy) in patients with advanced BTC after failure of first‐line treatment. Methods 24 patients with advanced BTC who failed first‐line treatment were admitted to our centre from March 2023 to August 2024 and ...
Xinni Chen, Feng Wang, Yuan Cheng, Mengran Cao, Kuimin Mei, Xiaoyuan Chu, Fang Dai, Xinlei Gong   +7 more
wiley   +1 more source

Recent Advances in Integrating Graphene into Polymeric Nanocomposite Hydrogels for Biomedical Applications

Macromolecular Bioscience, Volume 26, Issue 2, February 2026.
This review explores recent progress in graphene‐based polymeric nanocomposite hydrogels and how they enhance mechanical strength, electrical conductivity, and biocompatibility. It outlines key fabrication strategies and highlights applications in drug delivery, tissue engineering, and photothermal therapy, while also discussing the emerging role of ...
Abrar Hussain, Irum Batool, Khurram Shahzad, Syed Kumail Hussain Naqvi, Shahzaib Akhter, Ujala Zafar, Khaled Chawraba, Sang Hyun Park   +7 more
wiley   +1 more source

CUL4B promotes hepatocellular carcinoma progression and oxaliplatin resistance by facilitating FUS degradation. [PDF]

Cell Death Dis
Wei JD, Cheng K, Wu X, Zhang L, Wang Q, Liang Y, Zhu Z, Meng W, Chen W, Guan X, Yang H, Zhou L.   +11 more
europepmc   +1 more source

Natural Products in Cancer Prevention and Therapy: Current Challenges and Future Directions

MedComm, Volume 7, Issue 2, February 2026.
Natural products play a pivotal role in cancer therapy. They induce cancer cell death by reprogramming four metabolic pathways while precisely targeting the tumor microenvironment and immune cells. These compounds not only leverage novel delivery systems for innovative applications but also demonstrate unique therapeutic efficacy across clinical stages:
Ruimiao Qian, Jun Ge, Ni Fan, Zheng Sun, Chengcheng Zhao, Yujiao Sun, Yingpeng Li, Yunfei Li, Hui Fu   +8 more
wiley   +1 more source